Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Neurocrine Biosciences (NBIX) over the last 9 years, with Q4 2018 value amounting to $18.1 million.

  • Neurocrine Biosciences' Non-Current Deffered Revenue rose 7705.01% to $18.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $18.1 million, marking a year-over-year increase of 7705.01%. This contributed to the annual value of $18.1 million for FY2018, which is 7705.01% up from last year.
  • As of Q4 2018, Neurocrine Biosciences' Non-Current Deffered Revenue stood at $18.1 million, which was up 7705.01% from $12.1 million recorded in Q3 2018.
  • Over the past 5 years, Neurocrine Biosciences' Non-Current Deffered Revenue peaked at $18.1 million during Q4 2018, and registered a low of $1.9 million during Q4 2014.
  • Its 5-year average for Non-Current Deffered Revenue is $9.1 million, with a median of $10.2 million in 2015.
  • In the last 5 years, Neurocrine Biosciences' Non-Current Deffered Revenue plummeted by 529.77% in 2014 and then soared by 44507.19% in 2015.
  • Over the past 5 years, Neurocrine Biosciences' Non-Current Deffered Revenue (Quarter) stood at $1.9 million in 2014, then skyrocketed by 445.07% to $10.2 million in 2015, then changed by 0.0% to $10.2 million in 2016, then changed by 0.0% to $10.2 million in 2017, then soared by 77.05% to $18.1 million in 2018.
  • Its last three reported values are $18.1 million in Q4 2018, $12.1 million for Q3 2018, and $10.2 million during Q2 2018.